一种癌胚抗原特异性细胞疗法在体外和体内选择性靶向HLA杂合性缺失的肿瘤细胞
癌胚抗原(CEA)在多数结直肠肿瘤中高表达,但针对CEA的高活性疗法因正常肠上皮表达CEA可致严重结肠炎。本研究开发Tmod双信号整合器:CEA Tmod细胞含CEA激活的嵌合抗原受体和HLA-A*02触发的LIR-1抑制性受体,利用肿瘤HLA杂合性缺失保护正常组织。CEA Tmod细胞在体外和体内有效杀伤CEA表达肿瘤细胞,且混合HLA-A*02表达细胞时仍高选择肿瘤细胞;数据支持进一步开发CEA Tmod构建体作为结直肠癌治疗候选。
要点
- CEA Tmod细胞用CEA激活的CAR和HLA-A*02触发的LIR-1抑制性受体双信号整合。
- CEA Tmod细胞利用肿瘤HLA杂合性缺失保护正常组织免受on-target off-tumor毒性。
- CEA Tmod细胞体外和体内有效杀伤CEA表达肿瘤细胞,混合HLA-A*02表达细胞时仍高选择。
核心结论
- 这些数据支持进一步开发CEA Tmod构建体作为结直肠癌的治疗候选。
研究设计与样本
- 原文未报告研究设计与样本。
主要发现
- CEA Tmod细胞在体外和体内有效杀伤表达CEA的肿瘤细胞。
- 与传统CEA特异性T细胞受体转基因T细胞相比,CEA Tmod细胞即使与表达HLA-A*02的细胞混合时仍对肿瘤细胞高度选择。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The CEACAM5 gene product [carcinoembryonic antigen (CEA)] is an attractive target for colorectal cancer because of its high expression in virtually all colorectal tumors and limited expression in most healthy adult tissues. However, highly active CEA-directed investigational therapeutics have been reported to be toxic, causing severe colitis because CEA is expressed on normal gut epithelial cells. Here, we developed a strategy to address this toxicity problem: the Tmod dual-signal integrator. CEA Tmod cells use two receptors: a chimeric antigen receptor (CAR) activated by CEA and a leukocyte Ig-like receptor 1 (LIR-1)-based inhibitory receptor triggered by human leukocyte antigen (HLA)-A*02. CEA Tmod cells exploit instances of HLA heterozygous gene loss in tumors to protect the patient from on-target, off-tumor toxicity. CEA Tmod cells potently killed CEA-expressing tumor cells in vitro and in vivo. But in contrast to a traditional CEA-specific T cell receptor transgenic T cell, Tmod cells were highly selective for tumor cells even when mixed with HLA-A*02-expressing cells. These data support further development of the CEA Tmod construct as a therapeutic candidate for colorectal cancer.
引用
- Sandberg ML, Wang X, Martin AD, et al. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo. Sci Transl Med. 2022. PMID: 35235342. doi:10.1126/scitranslmed.abm0306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。